ArticleCardio-oncology (London, England)2026
The ROOT-CTRCD study: exploring the relationship of oral health to cancer therapy-related cardiac dysfunction in HER2-positive breast cancer patients.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The state of cardio-oncology in Oman: awareness, practices, and training needs among healthcare providers: a survey-based study.Cardio-oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer therapy-related cardiac dysfunction (CTRCD) is a significant complication of cancer therapy. While several factors contribute to its development, the role of oral health remains unexplored. This study examines the relationship between oral health, a potential modifiable risk factor, and the development of CTRCD in patients undergoing HER2-targeted therapy.
methodsA retrospective study was conducted at a tertiary oncology center (SQCCCRC) with integrated cardio-oncology and specialized dental services. Adult women with early-stage or locally advanced HER2-positive breast cancer who received anthracycline-trastuzumab or anthracycline-free trastuzumab regimens between 2022 and 2025 were screened. Among 604 patients treated with trastuzumab, 307 completed all planned cycles and had at least one year of follow-up. After excluding patients with prior chemotherapy, major cardiovascular comorbidities, smoking, chronic kidney disease, ischemic heart disease, heart failure, dyslipidemia, and established risk factors for periodontitis, 62 patients who developed cancer therapy–related cardiac dysfunction (CTRCD) and 65 matched controls were included in the final analysis. Oral health was assessed using the DMFT index and periodontal staging/grading based on baseline dental evaluations performed before initiation of chemotherapy containing trastuzumab. Patients were then categorized into good or poor oral health groups. CTRCD was diagnosed and classified using echocardiographic findings, with recovery time documented. The primary outcome was CTRCD incidence; secondary outcomes included recovery time and significant changes in left ventricular ejection fraction (LVEF).
resultsAmong patients with CTRCD, 64.5% had poor oral health, compared to 33.8% in the control group (p < 0.001). Poor oral health was significantly associated with higher CTRCD risk (OR = 3.54; 95% CI: 1.76–7.14), delayed recovery (8 weeks vs. 4 weeks, p = 0.011), and a 3-fold higher likelihood of significant EF decline (> 10%) (p = 0.0023). Associations with cardiac biomarkers (BNP and troponin) trended toward significance.
conclusionsPoor oral health is significantly associated with increased risk and delayed recovery of CTRCD in patients receiving HER2-targeted therapy. These findings highlight oral health as a modifiable risk factor that may impact cardiac and oncologic outcomes. Future randomized controlled trials are needed to investigate further the potential benefits of dental interventions in preventing CTRCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.